Contact

Therapeutic Anti-IgE Monoclonal Antibody Single Chain Variable Fragment (scFv) Safety and Immunomodulatory Effects After One Time Injection in Four Dogs.

Hammerberg et al., Veterinary Dermatology (2016) - PMID: 27426720

Product(s) used in this publication:  PepSpots™ Peptides on Cellulose

Abstract:

BACKGROUND:

The therapeutic monoclonal antibody omalizumab that is specific for IgE has proven to be an effective addition to the treatment of allergic disease in humans.

HYPOTHESIS/OBJECTIVES:

The aims of this study were to demonstrate the safety and immunomodulating effects of a single injection of a monoclonal antibody single chain variable fragments (scFv) specific for canine IgE in normal dogs.

ANIMALS:

Three normal dogs were bled for EDTA whole blood samples for 112 days post-injection (dpi). A fourth dog was monitored for 28 days.

METHODS:

Anti-IgE scFv was pegylated to minimize scFv dimerization. Four normal dogs were injected once subcutaneously with anti-IgE scFv at 1 mg/kg. Flow cytometry was performed on whole blood. Plasma levels of IgE were measured by ELISA.

RESULTS:

None of the four dogs showed signs of anaphylaxis. All dogs demonstrated decreases in IgE(+) cells in lymphocyte-gated events by 14 dpi. Dogs C and D returned to pre-injection levels by 21 days, whereas dogs A and B remained below pre-injection levels until Day 112. Similar differences were seen in IgE-bearing granulocyte-gated cells. Free plasma IgE decreased below pre-injection levels by 47% in Dog A and by 52% in Dog B at 112 days. Dogs C and D did not change by more than 32% from preinjection levels.

CONCLUSION:

A single injection of monomeric, pegylated scFv with high affinity for dog IgE was demonstrated to be safe. Marked reduction in IgE-bearing lymphocytes and granulocytes accompanied by reduced "free" plasma IgE level in two of four dogs is analogous to omalizumab in humans.

© 2016 ESVD and ACVD.

Stay in touch and be the first to receive the latest news!